While investors may have cheered the recent $74 billion bid that Bristol-Myers Squibb (BMY) made for Celgene (CELG), a pair of Congressional lawmakers want federal authorities to examine the extent to which such a deal may impede competition or cause higher drug prices for Americans.
In a letter sent last Friday to the Federal Trade Commission and the Department of Justice, Rep. Peter Welch (D-Vt.) and Rep. Francis Rooney (R-Fla.) expressed concern that the takeover could reduce treatment options for patients by giving Bristol-Myers access to product lines that may either compete with or complement its current portfolio of cancer drugs.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
The fact that I can make a comment on this article for free, but have to pay to read it, means that anyone can make a biased, untrue, crazy opinionated comment to try to sway whoever is reading. Nice job website design team. I’ll sell you my advice so I can read the article for free.